Document:

<PAGE>

                                                                    Exhibit 4.01

          This Note is a Global Security within the meaning of the Indenture
hereinafter referred to and is registered in the name of the Depository named
below or a nominee of the Depository. This Note is not exchangeable for Notes
registered in the name of a Person other than the Depository or its nominee
except in the limited circumstances described herein and in the Indenture, and
no transfer of this Note (other than a transfer of this Note as a whole by the
Depository to a nominee of the Depository or by a nominee of the Depository to
the Depository or another nominee of the Depository) may be registered except in
the limited circumstances described herein.

          Unless this certificate is presented by an authorized representative
of The Depository Trust Company, a New York corporation (the "Depository"), to
the Company or its agent for registration of transfer, exchange, or payment, and
any certificate issued is registered in the name of Cede & Co. or in such other
name as is requested by an authorized representative of the Depository (and any
payment is made to Cede & Co. or to such other entity as is requested by an
authorized representative of the Depository), ANY TRANSFER, PLEDGE, OR OTHER USE
HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL inasmuch as the
registered owner hereof, Cede & Co., has an interest herein.

                                 CITIGROUP INC.
                         5.850% NOTES DUE AUGUST 2, 2016

REGISTERED                                                            REGISTERED

                                                              CUSIP: 172967 DQ 1
                                                              ISIN: US172967DQ13
                                                          Common Code: 026336279

No. R-0001                                                     $________________

          CITIGROUP INC., a Delaware corporation (the "Company", which term
includes any successor Person under the Indenture), for value received, hereby
promises to pay to Cede & Co., or registered assigns, the principal sum of
$_____________ on August 2, 2016 and to pay interest thereon from and including
August 2, 2006 or from the most recent Interest Payment Date to which interest
has been paid or duly provided for, semi-annually, on February 2 and August 2 of
each year, commencing February 2, 2007, at the rate of 5.850% per annum, until
the principal hereof is paid or made available for payment. The interest so
payable, and punctually paid or duly provided for, on any Interest Payment Date
will, as provided in the Indenture, be paid to the Person in whose name this
Note is registered at the close of business on the Record Date for such
interest, which shall be the January 15 and July 15 (whether or not a Business
Day) immediately preceding such Interest Payment Date.

<PAGE>

          Any such interest not so punctually paid or duly provided for will
forthwith cease to be payable to the holder on such Record Date and may either
be paid to the Person in whose name this Note is registered at the close of
business on a subsequent Record Date, such subsequent Record Date to be not less
than five days prior to the date of payment of such defaulted interest, notice
whereof shall be given to holders of Notes of this series not less than 15 days
prior to such subsequent Record Date, or be paid at any time in any other lawful
manner not inconsistent with the requirements of any securities exchange on
which the Notes of this series may be listed, and upon such notice as may be
required by such exchange, all as more fully provided in the Indenture.

          Interest hereon will be calculated on the basis of a 360-day year
comprised of twelve 30-day months.

          If either an Interest Payment Date or the Maturity of the Notes falls
on a day that is not a Business Day, such Interest Payment Date or Maturity will
be the next succeeding Business Day. If a date for payment of interest or
principal on the Notes falls on a day that is not a business day in the place of
payment, such payment will be made on the next succeeding business day in such
place of payment as if made on the date the payment was due. No interest will
accrue on any amounts payable for the period from and after the due date for
payment of such principal or interest.

          For these purposes, "Business Day" means any day which is a day on
which commercial banks settle payments and are open for general business in The
City of New York.

          Payment of the principal of and interest on this Note will be made at
the office or agency of the Trustee maintained for that purpose in The City of
New York.

          Reference is hereby made to the further provisions of this Note set
forth on the reverse hereof, which further provisions shall for all purposes
have the same effect as if set forth at this place.

          Unless the certificate of authentication hereon has been executed by
the Trustee or by an authenticating agent on behalf of the Trustee by manual
signature, this Note shall not be entitled to any benefit under the Indenture or
be valid or obligatory for any purpose.

                                        2

<PAGE>

          IN WITNESS WHEREOF, the Company has caused this instrument to be duly
executed under its corporate seal.

Dated: August 2, 2006

                                        CITIGROUP INC.

                                        By:
                                            ------------------------------------
                                        Title: Chief Financial Officer

ATTEST:

By:
    ---------------------------------
Title: Assistant Secretary

                                        3

<PAGE>

          This is one of the Notes of the series issued under the
within-mentioned Indenture.

Dated: August 2, 2006

                                        THE BANK OF NEW YORK,
                                        as Trustee

                                        By:
                                            ------------------------------------
                                        Name:
                                              ----------------------------------
                                        Title:
                                               ---------------------------------

                                        -or-

                                        CITIBANK, N.A.,
                                        as Authenticating Agent

                                        By:
                                            ------------------------------------
                                        Name:
                                              ----------------------------------
                                        Title:
                                               ---------------------------------

                                        4

<PAGE>

          This Note is one of a duly authorized issue of Securities of the
Company (the "Notes"), issued and to be issued in one or more series under the
Indenture, dated as of March 15, 1987 (as amended and supplemented to date, the
"Indenture"), between the Company and The Bank of New York, as Trustee (the
"Trustee", which term includes any successor trustee under the Indenture), to
which Indenture and all indentures supplemental thereto reference is hereby made
for a statement of the respective rights, limitations of rights, duties and
immunities thereunder of the Company, the Trustee and the holders of the Notes
and of the terms upon which the Notes are, and are to be, authenticated and
delivered. This Note is one of the series designated on the face hereof,
initially limited in aggregate principal to $1,000,000,000.

          If an event of default (as defined in the Indenture) with respect to
Notes of this series shall occur and be continuing, the principal of the Notes
of this series may be declared due and payable in the manner and with the effect
provided in the Indenture.

          The Indenture contains provisions for defeasance at any time of the
entire indebtedness of this Note upon compliance by the Company with certain
conditions set forth in Sections 11.03 and 11.04 thereof, which provisions apply
to this Note.

          The Indenture contains provisions permitting the Company and the
Trustee, without the consent of the holders of the Securities, to establish,
among other things, the form and terms of any series of Securities issuable
thereunder by one or more supplemental indentures, and, with the consent of the
holders of not less than 66 2/3% in aggregate principal amount of Securities at
the time outstanding which are affected thereby, to modify the Indenture or any
supplemental indenture or the rights of the holders of Securities of such series
to be affected, provided that no such modification will (i) extend the fixed
maturity of any Securities, reduce the rate or extend the time of payment of
interest thereon, reduce the principal amount thereof or the premium, if any,
thereon, reduce the amount of the principal of Original Issue Discount
Securities payable on any date, change the currency in which Securities are
payable, or impair the right to institute suit for the enforcement of any such
payment on or after the maturity thereof, without the consent of the holder of
each Security so affected, or (ii) reduce the aforesaid percentage of Securities
of any series the consent of the holders of which is required for any such
modification without the consent of the holders of all Securities of such series
then outstanding, or (iii) modify, without the written consent of the Trustee,
the rights, duties or immunities of the Trustee.

          No reference herein to the Indenture and no provision of this Note or
of the Indenture shall alter or impair the obligation of the Company, which is
absolute and unconditional, to pay the principal of and interest on this Note at
the times, place and rate, and in the coin or currency, herein prescribed.

          This Note is a Global Security registered in the name of a nominee of
the Depository. This Note is exchangeable for Notes registered in the name of a
person other than the Depository or its nominee only in the limited
circumstances hereinafter described. Unless and until it is exchanged in whole
or in part for definitive Notes in certificated form, this Note may not be

                                        5

<PAGE>

transferred except as a whole by the Depository to a nominee of the Depository
or by a nominee of the Depository to the Depository or another nominee of the
Depository.

          The Notes represented by this Global Security are exchangeable for
definitive Notes in certificated form of like tenor as such Notes in
denominations of $100,000 and whole multiples of $1,000 in excess thereof only
if (i) the Depository notifies the Company that it is unwilling or unable to
continue as Depository for the Notes or (ii) the Depository ceases to be a
clearing agency registered under the Securities Exchange Act of 1934, as
amended, or (iii) the Company in its sole discretion decides to allow the Notes
to be exchanged for definitive Notes in registered form. Any Notes that are
exchangeable pursuant to the preceding sentence are exchangeable for
certificated Notes issuable in authorized denominations and registered in such
names as the Depository shall direct. As provided in the Indenture and subject
to certain limitations therein set forth, the transfer of definitive Notes in
certificated form is registrable in the register maintained by the Company in
The City of New York for such purpose, upon surrender of the definitive Note for
registration of transfer at the office or agency of the registrar, duly endorsed
by, or accompanied by a written instrument of transfer in form satisfactory to
the Company and the registrar duly executed by, the holder thereof or his
attorney duly authorized in writing, and thereupon one or more new Notes of this
series and of like tenor, of authorized denominations and for the same aggregate
principal amount, will be issued to the designated transferee or transferees.
Subject to the foregoing, this Note is not exchangeable, except for a Global
Security or Global Securities of this issue of the same principal amount to be
registered in the name of the Depository or its nominee.

          No service charge shall be made for any such registration of transfer
or exchange, but the Company may require payment of a sum sufficient to cover
any tax or other governmental charge payable in connection therewith.

          Prior to due presentment of this Note for registration of transfer,
the Company, the Trustee and any agent of the Company or the Trustee may treat
the Person in whose name this Note is registered as the owner hereof for all
purposes, whether or not this Note be overdue, and neither the Company, the
Trustee nor any such agent shall be affected by notice to the contrary.

          The Company will pay additional amounts ("Additional Amounts") to the
beneficial owner of any Note that is a non-United States person in order to
ensure that every net payment on such Note will not be less, due to payment of
U.S. withholding tax, than the amount then due and payable. For this purpose, a
"net payment" on a Note means a payment by the Company or a paying agent,
including payment of principal and interest, after deduction for any present or
future tax, assessment or other governmental charge of the United States. These
Additional Amounts will constitute additional interest on the Note.

          The Company will not be required to pay Additional Amounts, however,
in any of the circumstances described in items (1) through (13) below.

                                        6

<PAGE>

     (1)  Additional Amounts will not be payable if a payment on a Note is
          reduced as a result of any tax, assessment or other governmental
          charge that is imposed or withheld solely by reason of the beneficial
          owner:

          (a)  having a relationship with the United States as a citizen,
               resident or otherwise;

          (b)  having had such a relationship in the past or

          (c)  being considered as having had such a relationship.

     (2)  Additional Amounts will not be payable if a payment on a Note is
          reduced as a result of any tax, assessment or other governmental
          charge that is imposed or withheld solely by reason of the beneficial
          owner:

          (a)  being treated as present in or engaged in a trade or business in
               the United States;

          (b)  being treated as having been present in or engaged in a trade or
               business in the United States in the past or

          (c)  having or having had a permanent establishment in the United
               States.

     (3)  Additional Amounts will not be payable if a payment on a Note is
          reduced as a result of any tax, assessment or other governmental
          charge that is imposed or withheld in whole or in part by reason of
          the beneficial owner being or having been any of the following (as
          such terms are defined in the Internal Revenue Code of 1986, as
          amended):

          (a)  personal holding company;

          (b)  foreign personal holding company;

          (c)  foreign private foundation or other foreign tax-exempt
               organization;

          (d)  passive foreign investment company;

          (e)  controlled foreign corporation or

          (f)  corporation which has accumulated earnings to avoid United States
               federal income tax.

     (4)  Additional Amounts will not be payable if a payment on a Note is
          reduced as a result of any tax, assessment or other governmental
          charge that is imposed or withheld solely by reason of the beneficial
          owner owning or having owned, actually or constructively, 10 percent
          or more of the total combined voting power of all classes of stock of
          the Company entitled to vote or by reason of the beneficial owner
          being a bank that has invested in a Note as an extension of credit in
          the ordinary course of its trade or business.

For purposes of items (1) through (4) above, "beneficial owner" means a
fiduciary, settlor, beneficiary, member or shareholder of the holder if the
holder is an estate, trust, partnership, limited liability company, corporation
or other entity, or a person holding a power over an estate or trust
administered by a fiduciary holder.

                                        7

<PAGE>

     (5)  Additional Amounts will not be payable to any beneficial owner of a
          Note that is a:

          (a)  fiduciary;

          (b)  partnership;

          (c)  limited liability company or

          (d)  other fiscally transparent entity

          or that is not the sole beneficial owner of the Note, or any portion
          of the Note. However, this exception to the obligation to pay
          Additional Amounts will only apply to the extent that a beneficiary or
          settlor in relation to the fiduciary, or a beneficial owner or member
          of the partnership, limited liability company or other fiscally
          transparent entity, would not have been entitled to the payment of an
          Additional Amount had the beneficiary, settlor, beneficial owner or
          member received directly its beneficial or distributive share of the
          payment.

     (6)  Additional Amounts will not be payable if a payment on a Note is
          reduced as a result of any tax, assessment or other governmental
          charge that is imposed or withheld solely by reason of the failure of
          the beneficial owner or any other person to comply with applicable
          certification, identification, documentation or other information
          reporting requirements. This exception to the obligation to pay
          Additional Amounts will only apply if compliance with such reporting
          requirements is required by statute or regulation of the United States
          or by an applicable income tax treaty to which the United States is a
          party as a precondition to exemption from such tax, assessment or
          other governmental charge.

     (7)  Additional Amounts will not be payable if a payment on a Note is
          reduced as a result of any tax, assessment or other governmental
          charge that is collected or imposed by any method other than by
          withholding from a payment on a Note by the Company or a paying agent.

     (8)  Additional Amounts will not be payable if a payment on a Note is
          reduced as a result of any tax, assessment or other governmental
          charge that is imposed or withheld by reason of a change in law,
          regulation, or administrative or judicial interpretation that becomes
          effective more than 15 days after the payment becomes due or is duly
          provided for, whichever occurs later.

     (9)  Additional Amounts will not be payable if a payment on a Note is
          reduced as a result of any tax, assessment or other governmental
          charge that is imposed or withheld by reason of the presentation by
          the beneficial owner of a Note for payment more than 30 days after the
          date on which such payment becomes due or is duly provided for,
          whichever occurs later.

     (10) Additional Amounts will not be payable if a payment on a Note is
          reduced as a result of any:

                                        8

<PAGE>

          (a)  estate tax;

          (b)  inheritance tax;

          (c)  gift tax;

          (d)  sales tax;

          (e)  excise tax;

          (f)  transfer tax;

          (g)  wealth tax;

          (h)  personal property tax or

          (i)  any similar tax, assessment, withholding, deduction or other
               governmental charge.

     (11) Additional Amounts will not be payable if a payment on a Note is
          reduced as a result of any tax, assessment, or other governmental
          charge required to be withheld by any paying agent from a payment of
          principal or interest on a Note if such payment can be made without
          such withholding by any other paying agent.

     (12) Additional amounts will not be payable if a payment on a Note is
          reduced as a result of any tax, assessment or other governmental
          charge that is required to be made pursuant to any European Union
          directive on the taxation of savings income or any law implementing or
          complying with, or introduced to conform to, any such directive.

     (13) Additional Amounts will not be payable if a payment on a Note is
          reduced as a result of any combination of items (1) through (12)
          above.

          Except as specifically provided herein, the Company will not be
required to make any payment of any tax, assessment or other governmental charge
imposed by any government or a political subdivision or taxing authority of such
government.

          As used in this Note, "United States person" means:

          (a)  any individual who is a citizen or resident of the United States;

          (b)  any corporation, partnership or other entity created or organized
               in or under the laws of the United States;

          (c)  any estate if the income of such estate falls within the federal
               income tax jurisdiction of the United States regardless of the
               source of such income and

          (d)  any trust if a United States court is able to exercise primary
               supervision over its administration and one or more United States
               persons have the authority to control all of the substantial
               decisions of the trust.

          Additionally, "non-United States person" means a person who is not a
United States person, and "United States" means the states of the United States
of America and the District of Columbia, but excluding its territories and its
possessions.

                                        9

<PAGE>

          Except as provided below, the Notes may not be redeemed prior to
maturity.

     (1)  The Company may, at its option, redeem the Notes if:

          (a)  the Company becomes or will become obligated to pay Additional
               Amounts as described above;

          (b)  the obligation to pay Additional Amounts arises as a result of
               any change in the laws, regulations or rulings of the United
               States, or an official position regarding the application or
               interpretation of such laws, regulations or rulings, which change
               is announced or becomes effective on or after July 26, 2006 and

          (c)  the Company determines, in its business judgment, that the
               obligation to pay such Additional Amounts cannot be avoided by
               the use of reasonable measures available to it, other than
               substituting the obligor under the Notes or taking any action
               that would entail a material cost to the Company.

     (2)  The Company may also redeem the Notes, at its option, if:

          (a)  any act is taken by a taxing authority of the United States on or
               after July 26, 2006, whether or not such act is taken in relation
               to the Company or any affiliate, that results in a substantial
               probability that the Company will or may be required to pay
               Additional Amounts as described above;

          (b)  the Company determines, in its business judgment, that the
               obligation to pay such Additional Amounts cannot be avoided by
               the use of reasonable measures available to it, other than
               substituting the obligor under the Notes or taking any action
               that would entail a material cost to the Company and

          (c)  the Company receives an opinion of independent counsel to the
               effect that an act taken by a taxing authority of the United
               States results in a substantial probability that the Company will
               or may be required to pay the Additional Amounts described under
               above, and delivers to the Trustee a certificate, signed by a
               duly authorized officer, stating that based on such opinion the
               Company is entitled to redeem the Notes pursuant to their terms.

Any redemption of the Notes as set forth in clauses (1) or (2) above shall be in
whole, and not in part, and will be made at a redemption price equal to 100% of
the principal amount of the Notes Outstanding plus accrued interest thereon to
the date of redemption. Holders shall be given not less than 30 days nor more
than 60 days prior notice by the Trustee of the date fixed for such redemption.

          All terms used in this Note which are defined in the Indenture shall
have the meanings assigned to them in the Indenture. The Notes are governed by
the laws of the State of New York.

                                       10EX-10.1

 

Exhibit 10.1

July 19, 2006

Dear Per:

          This letter agreement (“Agreement”) confirms our discussion concerning your employment status
with Merck & Co., Inc. (“Merck” or the “Company”) and supersedes my letter to you dated July 17,
2006. As we discussed, as part of a general restructuring of Merck’s worldwide human health
business, your current position as President, Human Health – Intercontinental will be eliminated at
the close of business on September 30, 2006 and you will be separated from employment. Merck is
offering you severance arrangements set forth below, contingent on your timely acceptance and
nonrevocation of the terms set forth in this Agreement:

1. Employment Status.

	 	(a)	 	Transition Assignment. Effective July 13, 2006 you will be relieved of
operational responsibilities and your sole assignment will be to effectuate the full
transition of your responsibilities as President, Human Health — Intercontinental, under my
direction. Your status as an “officer” as defined in Rule 16a-1(f) under the Securities
Exchange Act of 1934 will end at the close of business on July 13, 2006. You agree to use
your best efforts to perform this assignment and such other duties as I may assign to you
and to otherwise conduct yourself in the best interests of the Company. Your grade and
base salary will remain at their current level and you will continue to be eligible to
participate in the Company’s employee benefit plans and programs, as they may be amended
from time to time, on the same terms and conditions applicable to Company employees at your
grade level. At my sole discretion, your employment status may be converted at any time to
paid inactive status prior to September 30, 2006. While on paid inactive status, your
grade and base salary will be unchanged; you will continue to receive monthly salary
payments; you will continue to accrue pension credit and be eligible to participate in the
plans that you elected under the flexible benefits program; provided, however, that you
will not be eligible to participate in the short term and long term disability benefit
plans which benefits you agree to waive.
	 
	 	(b)	 	Termination of Employment. Your employment will terminate on September 30,
2006 (“Separation Date”), provided that you have not terminated your employment by
resignation prior to the Separation Date. Your resignation will be deemed to occur in the
event that you engage in conduct inconsistent with your responsibilities and obligations as
a Merck employee or if you voluntarily terminate your employment by quitting, retiring or
commencing employment elsewhere. The termination of your employment on

 

 

Page 2 of 9

	 	 	 	the Separation Date
will be a “Separation from Service” (“Separation”) under the Merck & Co., Inc. Separation
Benefits Plan for Nonunion Employees (“Separation Plan”) and you will be eligible for the
benefits applicable to a “Separated Retirement Eligible Employee” described in the brochure
entitled “Separated Retirement Eligible Employee Brochure” (the “Brochure”) under the
Separation Plan. Attached to this letter are the summary plan description (“SPD”) that
describes the benefits available to you under the Separation Plan and the Brochure that
describes the effect of a separation on other benefits for a “Separated Retirement Eligible
Employee.”

2. Separation Benefits. Upon your Separation, you will receive the following separation
benefits:

	 	(a)	 	Separation Pay. Subject to paragraph 3(b) below, you will receive
seventy-eight (78) weeks’ pay as described in the SPD, payable in periodic installments in
accordance with the Company’s normal payroll periods, minus applicable deductions and
withholdings.
	 
	 	(b)	 	Retirement Plan. You will be eligible to retire from the Company directly from
employment status and receive pension benefits. You understand that you must timely submit
your retirement paperwork.
	 
	 	(c)	 	Outplacement. You will be eligible to receive Senior Executive Service
outplacement services over a period of twelve (12) months.
	 
	 	(d)	 	Life Insurance. You will be eligible to be considered a retiree for life
insurance plan purposes as described in the Brochure.
	 
	 	(e)	 	Medical and Dental Benefits. You will be eligible to select retiree medical
and dental benefits as described in the Brochure.
	 
	 	(f)	 	Equity Grants. You will be considered “retired” for purposes of your
outstanding unexercised stock options, restricted stock units, leader shares and
performance share units, in each case, if any. It is your responsibility to familiarize
yourself with the terms of your individual equity grants.
	 
	 	(g)	 	Special Payment in Lieu of EIP Bonus. Subject to paragraph 3(b) below, you
will receive a special payment of $510,000, minus applicable deductions and withholdings,
in lieu of an EIP bonus for your performance in 2006. Your deferral election, if any, with
respect to such EIP bonus will not apply to this special payment.

3. Payments.

	 	(a)	 	Generally. All payments made pursuant this Agreement will be based on your
current base salary and are subject to applicable deductions and withholding. Upon your
Separation, except for the payments described in this Agreement and the attached Brochure,
no other compensation will be paid to you or on your behalf.

 

 

Page 3 of 9

	 	(b)	 	Section 409A. Payments generally may not be made on account of separation from
service for six months following the termination of employment of a “Specified Employee” as
defined in Prop. Treas. Reg. Sec. 1.409A-1(i) or any successor thereto, which in general
includes the top 50 employees of a company ranked by compensation. You are a “Specified
Employee.” Thus, to the extent required by Section 409A of the Internal Revenue Code of
1986, as amended, no payments will be made to you prior to the first day of the seventh
month following termination of your employment. Instead, amounts that would otherwise have
been payable during the six months immediately following your Separation will be
accumulated and paid in a lump sum, without interest, as soon as administratively
practicable following such six month period (i.e., on or after April 1, 2007).

4. Deferral Program Account. Your Deferred Program Account, if applicable, will be paid
out to you in accordance with the terms and conditions of the Merck deferral program applicable to
separated employees, subject to paragraph 3(b) of this Agreement.

5. Lump Sum Payment. In January 2007, Merck will pay to you, subject to appropriate tax
withholding, a gross lump sum in the amount of $170,000. This lump sum payment is not subject to
paragraph 3(b) of this Agreement. As a condition of receiving this lump sum payment, you agree to
execute and return to me the release of claims attached hereto as Attachment “A” on or soon after
September 30, 2006. Merck’s obligation to pay this lump sum will not arise until the revocation
period for such executed release has passed without your revocation thereof.

6. Other Benefits.

	 	(a)	 	Financial Counseling. You may continue to participate in the Company’s
Executive Financial Services Program through the end of 2007 at the level established for
Management Committee members from time to time (currently, reimbursement up to $10,000 per
calendar year). In addition, through the end of 2009 the Company will provide you with tax
counseling, if required, relative to your tax obligations, if any, under the laws of any
country. The total cost of such tax/financial counseling payable by Merck under this
subparagraph (a) will not exceed $75,000.
	 	(b)	 	Relocation. If you choose to relocate to Norway, Merck, in accordance with
Company policy, will provide return trip airfare and temporary living for a maximum of
sixty days for you and your accompanying dependents and will ship your household goods back
to the point of origin or to some other mutually agreed upon area; provided that your
relocation must be completed by July 1, 2007, and further provided that Merck’s payment(s)
for these benefits will be reduced by any relocation reimbursement/expenses (for the same
move) you may be entitled to by arrangement with another employer. You will be eligible
for homesale assistance with buyout under Merck’s Relocation Policy, a copy of which has
already been provided to you. You understand and agree that your eligibility for this
benefit is contingent on your compliance with the procedures of this and other related
Company policies.

 

 

Page 4 of 9

7. Nondisparagement. You agree not to disparage Merck, its affiliates, subsidiaries, or
joint ventures, and their products, officers, directors, employees, former employees,
representatives and agents, in any way whatsoever.

8. Noncompete.

	 	(a)	 	For a period of eighteen months following your Separation Date, you agree not to
conduct business in competition with Merck. “Conduct business in competition with Merck”
means, for purposes of this Agreement,

(i) to be, or become being connected in any manner with, a Competitor as defined below,
directly or indirectly, as an individual or as a director, trustee, officer or employee
of, or debt or equity investor in, or consultant or other independent contractor to, a
Competitor, or through ownership, management, operation or control of a person or entity
that is a Competitor; provided that in no event shall ownership of 1% or less of the
outstanding equity securities of any issuer whose securities are registered under the
Securities Exchange Act of 1934, as amended, standing alone, be prohibited by this
subparagraph so long as you do not have, or exercise, any rights to manage, operate or
control the business of such issuer; or

(ii) to be or become an employee, consultant or other independent contractor, director,
trustee, or officer of any company, not defined below as a Competitor, that discovers,
develops, markets or sells pharmaceutical or biological products or vaccines, unless you
have first obtained the consent of Merck’s General Counsel. Your request for consent
must include the name of the company for which you would like to work (or otherwise
become associated), the nature of your proposed employment, association or relationship
with such company, and any other information requested by the General Counsel. The
consent of the General Counsel required hereunder will not be unreasonably withheld,
provided, however, that you understand and agree that the decision whether to grant any
such requested consent will be determined by the General Counsel in the exercise of his
or her sole discretion. No such consent will be effective unless it is set forth in a
signed, written communication from the General Counsel to you.

	 	(b)	 	“Competitor” means any of the following companies as well as their parents,
subsidiaries, affiliates and successors: Abbott Laboratories, Amgen, AstraZenica, Bristol
Myers Squibb, Glaxo Smith Kline, Genentech, Johnson & Johnson, Eli Lilly, Novartis/Chiron,
Pfizer, Roche/Hoffmann-La Roche, Sanofi/Adventis, Schering Plough and Wyeth.

9. Nonsolicitation. You agree not to solicit, entice, persuade, induce or otherwise
attempt to influence any person, who is employed by Merck, its subsidiaries or joint ventures on
the date of this Agreement, to leave the employ of Merck, its subsidiaries or joint ventures, by
(1) making initial contact with a Merck employee for such purpose or engaging in discussion with a
Merck employee about such purpose or result, (2) causing any third party to make initial contact
with a Merck employee for the purpose of soliciting, enticing, persuading or inducing them to leave
the

 

 

Page 5 of 9

employ of Merck, or (3) providing a third party information about any Merck employee for the
purpose of recruitment of that employee.

10. Confidential Information. You acknowledge and agree that, in the course of your
employment with the Company, you had access to trade secrets, and confidential and proprietary
business information (“Confidential Information”) owned by, or pertinent to, the Company and its
subsidiaries or joint ventures. You agree not to disclose Confidential Information.

11. Litigation. In connection with litigation, investigation, inquiry or proceedings
before a court, arbitrator, government or administrative agency or other tribunal, you may be asked
by Merck to testify as a witness or to provide information concerning matters you were or might
have been involved in during the course of your employment with Merck. You agree to cooperate
fully with Merck’s counsel by making yourself available to such counsel to discuss your information
or to review your testimony reasonably in advance of such litigation or proceedings, by making
yourself available to testify at depositions or trial as required or requested by Merck, and by
notifying Merck immediately upon becoming aware of any litigation, investigation, inquiry or
proceedings involving Merck. Other than travel expenses and applicable, or statutorily mandated,
witness fees, you agree that you will not be paid in connection with your testimony, appearance or
participation pursuant to this paragraph in such litigation or proceedings. You further agree that
you will not initiate or participate in any lawsuit or other legal action or administrative
proceeding against or involving Merck, except as such participation is solicited by Merck or
authorized by Merck, unless commanded to do so by a valid and lawfully issued subpoena. You agree
that if you are subjected to a subpoena requiring you to bear witness on matters concerning your
employment with or your knowledge about Merck, you will contact the Company immediately and
cooperate fully with the Company in its chosen manner of proceeding. Nothing in this provision
shall be construed as precluding you from cooperating with law enforcement or regulatory agencies
in connection with any lawful government inquiries.

12. Breach of Agreement and Forfeiture of Benefits.

	 	(a)	 	The forfeiture of benefits provision set forth in the SPD is incorporated by reference
into this Agreement with respect to all amounts and benefits payable hereunder.
	 
	 	(b)	 	Separate and apart from any other remedy that Merck may have, in the event that Merck
reasonably determines that you have breached or violated paragraph 7, 8, 9, 10 or 11 of
this Agreement, Merck’s obligation to pay amounts described in paragraphs 2(a), 2(g) and 5
of this Agreement will immediately cease as of the date of such breach or violation and
Merck (i) will be relieved of any further obligation to make such payments and (ii) will be
entitled to demand, and you agree to immediately tender, all benefits and payments
previously made to you hereunder.
	 
	 	(c)	 	You agree that your breach of paragraph 8, 9 or 10 of this Agreement will cause
immediate and irreparable injury to Merck and it is and will be impossible to estimate and
determine the damage that will be suffered by Merck in the event of your breach. You agree
that your breach of any of these paragraphs will cause immediate and

 

 

Page 6 of 9

	 	 	 	irreparable injury to Merck and that it is and will be impossible to estimate and determine the damage that will
be suffered in the event of a breach. Separate and apart from any other remedy that Merck
may have, you further agree that, in the event of such a breach, Merck will be entitled, in
addition to any other available remedies, to (i) temporary and permanent injunctive relief
from any such breach by you and by your employers, employees, partners, agents and
associates, of the terms set forth in this paragraph, without the necessity of proving
actual damages, or immediate or irreparable harm, or of posting a bond, (ii) an award of
liquidated damages equal to all monies paid to you or received by you in accordance with
paragraphs 2(a), 2(g) and 5 of this Agreement, and (iii) all associated attorney’s fees and
costs.

13. Reformation. You agree that if any portion(s) of paragraph(s) 8, 9, 10, 11 or 12 is
determined to be invalid, such determination will not affect the enforceability of the remaining
portions of such paragraph(s) and such paragraph(s) will be interpreted as if the invalid portions
had not been inserted. You agree that if such invalidity is caused by the length of any period of
time or the size of any area, then the period of time or the area, or both, will, without need of
further action by any party, be deemed to be reduced to a period or area that will cure the
invalidity.

14. Confidentiality. You understand that Merck may be required by law to publicly report
the terms of this Agreement. Otherwise, you agree to hold the existence of this Agreement and the
terms and conditions of this Agreement in strict confidence and you agree not to disclose, except
as may be required by law or legal process, any such information to any third party other than
members of your immediate family, tax authorities, tax consultants or legal advisors

15. Release. In consideration of the promises of the Company as set forth in this
Agreement, and with the intent to be bound legally, you agree to irrevocably RELEASE AND FOREVER
DISCHARGE Merck & Co., Inc., together with its benefit plans, subsidiaries and affiliates and their
officers, directors, employees, agents, predecessors, partners, successors, fiduciaries and assigns
(“Releasees”) from and with respect to any manner of actions, suits, debts, claims, demands
whatsoever in law or equity arising out of or in any way relating to your employment with the
Company or the termination of your employment, or arising out of or in any way relating to any
transaction, occurrence, act or omission or any loss, damage or injury occurring at any time up to
and including the date and time on which you sign this Agreement (“Claims”), including, but not
limited to (a) any and all Claims based upon any law, statute, ordinance, regulation, constitution
or executive order or based in contract, tort or common law or any other legal or equitable theory
of relief; (b) any and all Claims based on the Employee Retirement Income Security Act of 1974; (c)
any and all Claims arising under the civil rights laws of any federal, state or local jurisdiction,
including, but not limited to, Title VII of the Civil Rights Act of 1964; the Americans with
Disabilities Act; Sections 503 and 504 of the Rehabilitation Act; the Family and Medical Leave Act;
the Age Discrimination in Employment Act; the Pennsylvania Human Relations Act; and the New Jersey
Law Against Discrimination; (d) any and all Claims under any whistleblower laws or whistleblower
provisions of other laws including, but not limited to, the New Jersey Conscientious Employee
Protection Act; and (e) any and all Claims for counsel fees or costs.

 

 

Page 7 of 9

     You understand that by signing this Agreement, you are waiving any and all Claims against any
and all Releasees released by this Agreement to the greatest extent allowable under law. Nothing
in this paragraph shall be read as a waiver of any vested rights in any savings or pension plan.

16. No Representation. You acknowledge that no promise, other than the promises in this
Agreement, have been made to you and that in signing this Agreement you are not relying upon any
statement or representation made by or on behalf of the Releasees and each or any of them
concerning the merits of any Claims or the nature, amount, extent or duration of any damages
relating to any Claims or the amount of any money, benefits, or compensation due you or claimed by
you, or concerning the Agreement or concerning any other thing or matter.

17. Voluntariness. You agree that you are relying solely upon your own judgment; that you
are legally competent to sign this Agreement; that you are signing this Agreement of your free
will; that you have read and understood the Agreement before signing it; and that you are signing
this Agreement in exchange for consideration that you believe is satisfactory and adequate.

18. No Admissions. You agree and acknowledge that neither the offer of these arrangements
nor this Agreement will be construed as an admission or as evidence that Merck or its agents have
failed in any way to act properly in connection with your employment or the termination thereof.
To the contrary, the Company specifically denies any wrongful or unlawful treatment towards you.
This Agreement has been proposed by the Company solely for the purpose of reaching a mutually
acceptable resolution of issues you have raised arising out of the termination of your employment.

19. Applicable Law. You acknowledge and agree that your employment relationship with
Merck is governed solely and exclusively under the laws of the State of New Jersey and the United
States and that any question as to the scope, interpretation and effect of this Agreement will be
resolved under the substantive and procedural laws of the State of New Jersey without giving effect
to any conflict of laws provisions. In the event that Merck or a subsidiary of Merck is deemed or
found to owe you severance pay (“Other Severance Pay”) under the laws or regulations of any other
state or country, amounts payable under paragraphs 2(a), 2(g) and 5 of this Agreement will be
reduced by the amount of such Other Severance Pay.

20. Severability. All provisions and portions of this Agreement are severable. If any
provision or portion of this Agreement or the application of any provision or portion of the
Agreement will be determined to be invalid or unenforceable to any extent or for any reason, all
other provisions and portions of this Agreement will remain in full force and effect and will
continue to be enforceable to the fullest and greatest extent permitted by law.

21. Amendment, Termination of Plans. Merck retains the right (to the extent permitted by
law) to amend or terminate the Separation Plan and any benefit or plan described in the SPD and/or
the Brochure (or otherwise) at any time, and nothing in this Agreement affects or alters that
right. While it has no current intention to do so, Merck also may extend, or enhance, the
Separation Plan in the future. If you sign and return the Agreement, any later amendment or

 

 

Page 8 of 9

termination will not decrease the amount of Separation Pay or the other Separation Benefits you are
eligible to receive as described in this Agreement.

22. Complete Agreement. This Agreement constitutes the complete and final agreement
between the parties and supersedes and replaces all prior or contemporaneous agreements,
negotiations, or discussions relating to the subject matter of this Agreement.

     In accordance with the federal Older Workers’ Benefit Protection Act of 1990, you have
forty-five (45) days within which to consider whether to sign the Agreement. Should you choose to
sign this Agreement, you are entitled to revoke your acceptance at any time within seven (7)
calendar days after signing it. If revoked by you within that time period, the Agreement will be
null and void for all purposes. The Agreement will not become effective or enforceable until the
revocation period has expired. Lastly, you have the right to consult with an attorney before
signing this Agreement.

     Please indicate your acceptance of this Agreement by signing and dating this letter and
returning it to me. A duplicate of this letter, signed by me, is enclosed for your records.

	 	 	 	 	 
	 

	 	Very truly yours,
	 	 
	 
	 	 	 	 
	 

	 	/s/ Peter H. Loescher	 	 
	 

	 	 	 	 
	 

	 	Peter H. Loescher	 	 
	 

	 	President, Global Human Health	 	 
	 
	 	 	 	 
	ACCEPTED:
	 	 	 	 
	 
	 	 	 	 
	/s/ Per Wold-Olsen

	 	               Dated: July 28, 2006	 	 
	 

Per Wold-Olsen

	 	 	 	 

 

 

Page 9 of 9

Attachment “A”

RELEASE AND WAIVER OF CLAIMS

     In consideration of the lump sum to be paid to me by Merck & Co., Inc. (“Merck” or “the
Company”), as set forth in paragraph 5 of the agreement between me and Merck dated July 19, 2006
(“the Agreement”), and with the intent to be bound legally, I agree to irrevocably RELEASE AND
FOREVER DISCHARGE Merck & Co., Inc., together with its benefit plans, subsidiaries and affiliates
and their officers, directors, employees, agents, predecessors, partners, successors, fiduciaries
and assigns (“Releasees”) from and with respect to any manner of actions, suits, debts, claims,
demands whatsoever in law or equity arising out of or in any way relating to my employment with the
Company or the termination of my employment, or arising out of or in any way relating to any
transaction, occurrence, act or omission or any loss, damage or injury occurring at any time up to
and including the date and time on which I sign this Release (“Claims”), including, but not limited
to (a) any and all Claims based upon any law, statute, ordinance, regulation, constitution or
executive order or based in contract, tort or common law or any other legal or equitable theory of
relief; (b) any and all Claims based on the Employee Retirement Income Security Act of 1974; (c)
any and all Claims arising under the civil rights laws of any federal, state or local jurisdiction,
including, but not limited to, Title VII of the Civil Rights Act of 1964; the Americans with
Disabilities Act; Sections 503 and 504 of the Rehabilitation Act; the Family and Medical Leave Act;
the Age Discrimination in Employment Act; the Pennsylvania Human Relations Act; and the New Jersey
Law Against Discrimination; (d) any and all Claims under any whistleblower laws or whistleblower
provisions of other laws including, but not limited to, the New Jersey Conscientious Employee
Protection Act; and (e) any and all Claims for counsel fees or costs.

     I understand that by signing this Release, I am waiving any and all Claims against any and all
Releasees released by this Release to the greatest extent allowable under law. Nothing in this
Release shall be read as a waiver of any vested rights in any savings or pension plan. I have had
45 days to consider the terms of this Release and I have been advised of my right to have my
counsel review this Release before I sign it. I have the right to revoke my agreement to the terms
of this Release by notifying Merck in writing within 7 calendar days after executing the Release.

	 	 	 
	Accepted:
	 	 
	 
	 	 
	/s/ Per Wold-Olsen
	 	 
	 

Per Wold-Olsen

	 	 
	 
	 	 
	Dated: July 28, 2006

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00107-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00107-of-00352.parquet"}]]